APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptic Ulcer Medication

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptic Ulcer Medication Market Analysis and Forecast 2026-2032

Report ID 174023500229 December 2025193 pages

Choose your research edition.

Industry ResearchPeptic Ulcer Medication Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptic Ulcer Medication Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Peptic Ulcer Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptic Ulcer Medication Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptic Ulcer Medication Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peptic Ulcer Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptic Ulcer Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptic Ulcer Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptic Ulcer Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptic Ulcer Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peptic Ulcer Medication include AstraZeneca, Chongqing Lummy Pharmaceutical, CTTQ, Jumpcan Pharmaceutical, Livzon Pharmaceutical, Luoxin Pharmaceuticals, Youcare Pharmaceutical, Jiangsu Aosaikang Pharmaceutical and Teva Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptic Ulcer Medication, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptic Ulcer Medication, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptic Ulcer Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptic Ulcer Medication revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptic Ulcer Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptic Ulcer Medication revenue, projected growth trends, production technology, application and end-user industry.

Peptic Ulcer Medication Segment by Company

AstraZeneca

Chongqing Lummy Pharmaceutical

CTTQ

Jumpcan Pharmaceutical

Livzon Pharmaceutical

Luoxin Pharmaceuticals

Youcare Pharmaceutical

Jiangsu Aosaikang Pharmaceutical

Teva Pharmaceuticals

Eisai

Takeda

Zhejiang Conba Pharmaceutical

Peptic Ulcer Medication Segment by Type

Proton Pump Inhibitors

Antacids

H2-Receptor Antagonists

Others

Peptic Ulcer Medication Segment by Application

Hospital and Clinic

Pharmacy

Peptic Ulcer Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptic Ulcer Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptic Ulcer Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptic Ulcer Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptic Ulcer Medication in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptic Ulcer Medication company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptic Ulcer Medication revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptic Ulcer Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Proton Pump Inhibitors Major Player Table 3. Antacids Major Player Table 4. H2-Receptor Antagonists Major Player Table 5. Others Major Player Table 6. Global Peptic Ulcer Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital and Clinic Major Player Table 8. Pharmacy Major Player Table 9. Peptic Ulcer Medication Industry Trends Table 10. Peptic Ulcer Medication Industry Drivers Table 11. Peptic Ulcer Medication Industry Opportunities and Challenges Table 12. Peptic Ulcer Medication Industry Restraints Table 13. Global Peptic Ulcer Medication Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Peptic Ulcer Medication Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Peptic Ulcer Medication Market Share by Region (2021-2026) Table 16. Global Peptic Ulcer Medication Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Peptic Ulcer Medication Market Share by Region (2027-2032) Table 18. Global Peptic Ulcer Medication Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Peptic Ulcer Medication Revenue Market Share by Players (2021-2026) Table 20. Global Peptic Ulcer Medication Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Peptic Ulcer Medication Key Players Headquarters & Area Served Table 22. Global Peptic Ulcer Medication Players, Product Type & Application Table 23. Global Peptic Ulcer Medication Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Peptic Ulcer Medication by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Peptic Ulcer Medication Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Peptic Ulcer Medication Revenue Market Share by Type (2021-2026) Table 30. Global Peptic Ulcer Medication Revenue Market Share by Type (2027-2032) Table 31. Global Peptic Ulcer Medication Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Peptic Ulcer Medication Revenue Market Share by Application (2021-2026) Table 35. Global Peptic Ulcer Medication Revenue Market Share by Application (2027-2032) Table 36. AstraZeneca Company Information Table 37. AstraZeneca Business Overview Table 38. AstraZeneca Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. AstraZeneca Peptic Ulcer Medication Product Portfolio Table 40. AstraZeneca Recent Development Table 41. Chongqing Lummy Pharmaceutical Company Information Table 42. Chongqing Lummy Pharmaceutical Business Overview Table 43. Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 45. Chongqing Lummy Pharmaceutical Recent Development Table 46. CTTQ Company Information Table 47. CTTQ Business Overview Table 48. CTTQ Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. CTTQ Peptic Ulcer Medication Product Portfolio Table 50. CTTQ Recent Development Table 51. Jumpcan Pharmaceutical Company Information Table 52. Jumpcan Pharmaceutical Business Overview Table 53. Jumpcan Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Jumpcan Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 55. Jumpcan Pharmaceutical Recent Development Table 56. Livzon Pharmaceutical Company Information Table 57. Livzon Pharmaceutical Business Overview Table 58. Livzon Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Livzon Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 60. Livzon Pharmaceutical Recent Development Table 61. Luoxin Pharmaceuticals Company Information Table 62. Luoxin Pharmaceuticals Business Overview Table 63. Luoxin Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Luoxin Pharmaceuticals Peptic Ulcer Medication Product Portfolio Table 65. Luoxin Pharmaceuticals Recent Development Table 66. Youcare Pharmaceutical Company Information Table 67. Youcare Pharmaceutical Business Overview Table 68. Youcare Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Youcare Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 70. Youcare Pharmaceutical Recent Development Table 71. Jiangsu Aosaikang Pharmaceutical Company Information Table 72. Jiangsu Aosaikang Pharmaceutical Business Overview Table 73. Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 75. Jiangsu Aosaikang Pharmaceutical Recent Development Table 76. Teva Pharmaceuticals Company Information Table 77. Teva Pharmaceuticals Business Overview Table 78. Teva Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Teva Pharmaceuticals Peptic Ulcer Medication Product Portfolio Table 80. Teva Pharmaceuticals Recent Development Table 81. Eisai Company Information Table 82. Eisai Business Overview Table 83. Eisai Peptic Ulcer Medication Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eisai Peptic Ulcer Medication Product Portfolio Table 85. Eisai Recent Development Table 86. Takeda Company Information Table 87. Takeda Business Overview Table 88. Takeda Peptic Ulcer Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Takeda Peptic Ulcer Medication Product Portfolio Table 90. Takeda Recent Development Table 91. Zhejiang Conba Pharmaceutical Company Information Table 92. Zhejiang Conba Pharmaceutical Business Overview Table 93. Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Product Portfolio Table 95. Zhejiang Conba Pharmaceutical Recent Development Table 96. North America Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Peptic Ulcer Medication Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Peptic Ulcer Medication Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Peptic Ulcer Medication Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Peptic Ulcer Medication Revenue by Country (US$ Million) & (2027-2032) Table 110. China Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 111. China Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 112. China Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 113. China Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Peptic Ulcer Medication Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Peptic Ulcer Medication Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Peptic Ulcer Medication Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Peptic Ulcer Medication Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Peptic Ulcer Medication Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Peptic Ulcer Medication Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Peptic Ulcer Medication Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Peptic Ulcer Medication Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Peptic Ulcer Medication Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Peptic Ulcer Medication Image Figure 2. Global Peptic Ulcer Medication Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptic Ulcer Medication Market Size Share 2021 VS 2025 VS 2032 Figure 4. Proton Pump Inhibitors Image Figure 5. Antacids Image Figure 6. H2-Receptor Antagonists Image Figure 7. Others Image Figure 8. Global Peptic Ulcer Medication Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Peptic Ulcer Medication Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital and Clinic Image Figure 11. Pharmacy Image Figure 12. Global Peptic Ulcer Medication Market Size (US$ Million) & (2021-2032) Figure 13. Global Peptic Ulcer Medication Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Peptic Ulcer Medication Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Peptic Ulcer Medication Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Peptic Ulcer Medication Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peptic Ulcer Medication Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Peptic Ulcer Medication Revenue Market Share by Type (2021-2032) Figure 20. Global Peptic Ulcer Medication Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Peptic Ulcer Medication Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Peptic Ulcer Medication Revenue Market Share by Application (2021-2032) Figure 23. North America Peptic Ulcer Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Peptic Ulcer Medication Revenue Share by Type (2021-2032) Figure 25. North America Peptic Ulcer Medication Revenue Share by Application (2021-2032) Figure 26. North America Peptic Ulcer Medication Revenue Share by Country (2021-2032) Figure 27. United States Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Peptic Ulcer Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Peptic Ulcer Medication Revenue Share by Type (2021-2032) Figure 32. Europe Peptic Ulcer Medication Revenue Share by Application (2021-2032) Figure 33. Europe Peptic Ulcer Medication Revenue Share by Country (2021-2032) Figure 34. Germany Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Peptic Ulcer Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Peptic Ulcer Medication Revenue Share by Type (2021-2032) Figure 44. China Peptic Ulcer Medication Revenue Share by Application (2021-2032) Figure 45. Asia Peptic Ulcer Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Peptic Ulcer Medication Revenue Share by Type (2021-2032) Figure 47. Asia Peptic Ulcer Medication Revenue Share by Application (2021-2032) Figure 48. Asia Peptic Ulcer Medication Revenue Share by Region (2021-2032) Figure 49. Japan Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Peptic Ulcer Medication Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Peptic Ulcer Medication Revenue Share by Type (2021-2032) Figure 57. SAMEA Peptic Ulcer Medication Revenue Share by Application (2021-2032) Figure 58. SAMEA Peptic Ulcer Medication Revenue Share by Country (2021-2032) Figure 59. Brazil Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Peptic Ulcer Medication Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Proton Pump Inhibitors
  • Antacids
  • H2-Receptor Antagonists
  • Others
Applications
  • Hospital and Clinic
  • Pharmacy
Companies covered
  • AstraZeneca
  • Chongqing Lummy Pharmaceutical
  • CTTQ
  • Jumpcan Pharmaceutical
  • Livzon Pharmaceutical
  • Luoxin Pharmaceuticals
  • Youcare Pharmaceutical
  • Jiangsu Aosaikang Pharmaceutical
  • Teva Pharmaceuticals
  • Eisai
  • Takeda
  • Zhejiang Conba Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptic Ulcer Medication Market by Type
  3. 1.2.1 Global Peptic Ulcer Medication Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Proton Pump Inhibitors
  5. 1.2.3 Antacids
  6. 1.2.4 H2-Receptor Antagonists
  7. 1.2.5 Others
  8. 1.3 Peptic Ulcer Medication Market by Application
  9. 1.3.1 Global Peptic Ulcer Medication Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital and Clinic
  11. 1.3.3 Pharmacy
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Peptic Ulcer Medication Market Dynamics
  1. 2.1 Peptic Ulcer Medication Industry Trends
  2. 2.2 Peptic Ulcer Medication Industry Drivers
  3. 2.3 Peptic Ulcer Medication Industry Opportunities and Challenges
  4. 2.4 Peptic Ulcer Medication Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptic Ulcer Medication Market Perspective (2021-2032)
  2. 3.2 Global Peptic Ulcer Medication Growth Trends by Region
  3. 3.2.1 Global Peptic Ulcer Medication Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptic Ulcer Medication Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptic Ulcer Medication Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptic Ulcer Medication Revenue by Players
  2. 4.1.1 Global Peptic Ulcer Medication Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptic Ulcer Medication Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptic Ulcer Medication Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptic Ulcer Medication Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptic Ulcer Medication Key Players Headquarters & Area Served
  7. 4.4 Global Peptic Ulcer Medication Players, Product Type & Application
  8. 4.5 Global Peptic Ulcer Medication Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptic Ulcer Medication Market CR5 and HHI
  11. 4.6.3 2025 Peptic Ulcer Medication Tier 1, Tier 2, and Tier 3
5 Peptic Ulcer Medication Market Size by Type
  1. 5.1 Global Peptic Ulcer Medication Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 5.3 Global Peptic Ulcer Medication Revenue Market Share by Type (2021-2032)
6 Peptic Ulcer Medication Market Size by Application
  1. 6.1 Global Peptic Ulcer Medication Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptic Ulcer Medication Revenue by Application (2021-2032)
  3. 6.3 Global Peptic Ulcer Medication Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca Peptic Ulcer Medication Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 Chongqing Lummy Pharmaceutical
  8. 7.2.1 Chongqing Lummy Pharmaceutical Company Information
  9. 7.2.2 Chongqing Lummy Pharmaceutical Business Overview
  10. 7.2.3 Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Chongqing Lummy Pharmaceutical Peptic Ulcer Medication Product Portfolio
  12. 7.2.5 Chongqing Lummy Pharmaceutical Recent Developments
  13. 7.3 CTTQ
  14. 7.3.1 CTTQ Company Information
  15. 7.3.2 CTTQ Business Overview
  16. 7.3.3 CTTQ Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CTTQ Peptic Ulcer Medication Product Portfolio
  18. 7.3.5 CTTQ Recent Developments
  19. 7.4 Jumpcan Pharmaceutical
  20. 7.4.1 Jumpcan Pharmaceutical Company Information
  21. 7.4.2 Jumpcan Pharmaceutical Business Overview
  22. 7.4.3 Jumpcan Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Jumpcan Pharmaceutical Peptic Ulcer Medication Product Portfolio
  24. 7.4.5 Jumpcan Pharmaceutical Recent Developments
  25. 7.5 Livzon Pharmaceutical
  26. 7.5.1 Livzon Pharmaceutical Company Information
  27. 7.5.2 Livzon Pharmaceutical Business Overview
  28. 7.5.3 Livzon Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Livzon Pharmaceutical Peptic Ulcer Medication Product Portfolio
  30. 7.5.5 Livzon Pharmaceutical Recent Developments
  31. 7.6 Luoxin Pharmaceuticals
  32. 7.6.1 Luoxin Pharmaceuticals Company Information
  33. 7.6.2 Luoxin Pharmaceuticals Business Overview
  34. 7.6.3 Luoxin Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Luoxin Pharmaceuticals Peptic Ulcer Medication Product Portfolio
  36. 7.6.5 Luoxin Pharmaceuticals Recent Developments
  37. 7.7 Youcare Pharmaceutical
  38. 7.7.1 Youcare Pharmaceutical Company Information
  39. 7.7.2 Youcare Pharmaceutical Business Overview
  40. 7.7.3 Youcare Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Youcare Pharmaceutical Peptic Ulcer Medication Product Portfolio
  42. 7.7.5 Youcare Pharmaceutical Recent Developments
  43. 7.8 Jiangsu Aosaikang Pharmaceutical
  44. 7.8.1 Jiangsu Aosaikang Pharmaceutical Company Information
  45. 7.8.2 Jiangsu Aosaikang Pharmaceutical Business Overview
  46. 7.8.3 Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Jiangsu Aosaikang Pharmaceutical Peptic Ulcer Medication Product Portfolio
  48. 7.8.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
  49. 7.9 Teva Pharmaceuticals
  50. 7.9.1 Teva Pharmaceuticals Company Information
  51. 7.9.2 Teva Pharmaceuticals Business Overview
  52. 7.9.3 Teva Pharmaceuticals Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Teva Pharmaceuticals Peptic Ulcer Medication Product Portfolio
  54. 7.9.5 Teva Pharmaceuticals Recent Developments
  55. 7.10 Eisai
  56. 7.10.1 Eisai Company Information
  57. 7.10.2 Eisai Business Overview
  58. 7.10.3 Eisai Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eisai Peptic Ulcer Medication Product Portfolio
  60. 7.10.5 Eisai Recent Developments
  61. 7.11 Takeda
  62. 7.11.1 Takeda Company Information
  63. 7.11.2 Takeda Business Overview
  64. 7.11.3 Takeda Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Takeda Peptic Ulcer Medication Product Portfolio
  66. 7.11.5 Takeda Recent Developments
  67. 7.12 Zhejiang Conba Pharmaceutical
  68. 7.12.1 Zhejiang Conba Pharmaceutical Company Information
  69. 7.12.2 Zhejiang Conba Pharmaceutical Business Overview
  70. 7.12.3 Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Zhejiang Conba Pharmaceutical Peptic Ulcer Medication Product Portfolio
  72. 7.12.5 Zhejiang Conba Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Peptic Ulcer Medication Revenue (2021-2032)
  2. 8.2 North America Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptic Ulcer Medication Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptic Ulcer Medication Revenue by Type (2027-2032)
  5. 8.3 North America Peptic Ulcer Medication Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptic Ulcer Medication Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptic Ulcer Medication Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptic Ulcer Medication Revenue by Application (2027-2032)
  9. 8.5 North America Peptic Ulcer Medication Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptic Ulcer Medication Revenue by Country
  11. 8.6.1 North America Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptic Ulcer Medication Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptic Ulcer Medication Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peptic Ulcer Medication Revenue (2021-2032)
  2. 9.2 Europe Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptic Ulcer Medication Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptic Ulcer Medication Revenue by Type (2027-2032)
  5. 9.3 Europe Peptic Ulcer Medication Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptic Ulcer Medication Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptic Ulcer Medication Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptic Ulcer Medication Revenue by Application (2027-2032)
  9. 9.5 Europe Peptic Ulcer Medication Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptic Ulcer Medication Revenue by Country
  11. 9.6.1 Europe Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptic Ulcer Medication Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptic Ulcer Medication Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peptic Ulcer Medication Revenue (2021-2032)
  2. 10.2 China Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 10.2.1 China Peptic Ulcer Medication Revenue by Type (2021-2026)
  4. 10.2.2 China Peptic Ulcer Medication Revenue by Type (2027-2032)
  5. 10.3 China Peptic Ulcer Medication Revenue Share by Type (2021-2032)
  6. 10.4 China Peptic Ulcer Medication Revenue by Application (2021-2032)
  7. 10.4.1 China Peptic Ulcer Medication Revenue by Application (2021-2026)
  8. 10.4.2 China Peptic Ulcer Medication Revenue by Application (2027-2032)
  9. 10.5 China Peptic Ulcer Medication Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptic Ulcer Medication Revenue (2021-2032)
  2. 11.2 Asia Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptic Ulcer Medication Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptic Ulcer Medication Revenue by Type (2027-2032)
  5. 11.3 Asia Peptic Ulcer Medication Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptic Ulcer Medication Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptic Ulcer Medication Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptic Ulcer Medication Revenue by Application (2027-2032)
  9. 11.5 Asia Peptic Ulcer Medication Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptic Ulcer Medication Revenue by Country
  11. 11.6.1 Asia Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptic Ulcer Medication Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptic Ulcer Medication Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptic Ulcer Medication Revenue (2021-2032)
  2. 12.2 SAMEA Peptic Ulcer Medication Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptic Ulcer Medication Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptic Ulcer Medication Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptic Ulcer Medication Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptic Ulcer Medication Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptic Ulcer Medication Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptic Ulcer Medication Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptic Ulcer Medication Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptic Ulcer Medication Revenue by Country
  11. 12.6.1 SAMEA Peptic Ulcer Medication Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptic Ulcer Medication Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptic Ulcer Medication Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst